CorTec Earns Second FDA Breakthrough Device Designation

CorTec GmbH, a leading company in brain-computer interfaces (BCI), has received a second FDA Breakthrough Device Designation for its Brain Interchange™ system, now covering communication. This recognition includes non-progressive quadriplegia, enabling control of a computer cursor via thought alone.

This second designation solidifies CorTec’s innovative platform, which spans both therapeutic and assistive domains within one implant. The Brain Interchange™ system offers cortical stimulation for stroke recovery and decodes intentions for facilitating communication. These designations highlight CorTec's unique position in the BCI field, notably for stroke motor rehabilitation.

Brain Interchange™ continues to be evaluated in clinical studies, demonstrating significant technological reliability and potential to improve patient autonomy across various neurological conditions. This platform highlights CorTec's ongoing commitment to advancing BCI applications.